Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Division of Clinical Pharmacology, Centre for Interdisciplinary Research on
Language :
English
Title :
Glucose-lowering agents and risk of cardiac arrhythmias.
Lee TW, Lee TI, Lin YK, et al. Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies. Cell Mol Life Sci. 2021; 78 (3): 923–934.
Boulmpou A, Patoulias D, Papadopoulos CE, et al. Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. Acta Cardiol. 2022; 1–6. DOI: 10.1080/00015385.2022.2087839.
Shi W, Zhang W, Zhang D, et al. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: a network meta-analysis. Heart Rhythm. 2021; 18 (7): 1090–1096.
Li W, Chen X, Xie X, et al. Comparison of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022; 79 (3): 281–288.
Sfairopoulos D, Zhang N, Wang Y, et al. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. 2022; 24 (1): 20–30.
Fauchier G, Bisson A, Bodin A, et al. Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus. Diabetologia. 2021; 64 (11): 2602–2605.
